{
    "Trade/Device Name(s)": [
        "NADiA\u00ae ProsVue \u2122"
    ],
    "Submitter Information": "Iris Molecular Diagnostics, A Division of IRIS International, Inc.",
    "510(k) Number": "K101185",
    "Predicate Device Reference 510(k) Number(s)": [
        "K062694"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OWM"
    ],
    "Summary Letter Date": "September 5, 2011",
    "Summary Letter Received Date": "September 7, 2011",
    "Submission Date": "September 19, 2011",
    "Regulation Number(s)": [
        "21 CFR 866.6040"
    ],
    "Regulation Name(s)": [
        "Gene expression profiling test system for breast cancer prognosis"
    ],
    "Analyte Class(es)": [
        "cancer molecular"
    ],
    "Analyte(s)": [
        "Prostate specific antigen (PSA)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [
        ""
    ],
    "Instrument(s)/Platform(s)": [
        "Applied Biosystems 7500 Fast Dx Real-Time PCR instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Immuno-PCR",
        "Two-site immunoassay",
        "PCR detection"
    ],
    "Methodologies": [
        "Gene expression profiling",
        "PCR-based quantitation"
    ],
    "Submission Type(s)": [
        "Assay",
        "Software",
        "Reagent",
        "Control",
        "Calibrator"
    ],
    "Document Summary": "FDA 510(k) summary for NADiA ProsVue immuno-PCR assay to determine PSA slope as a prognostic marker for prostate cancer recurrence risk post-prostatectomy",
    "Indications for Use Summary": "Aids in identifying prostate cancer patients at reduced risk for recurrence following radical prostatectomy by determining the rate of change of serum total PSA; not intended for diagnosis or monitoring.",
    "fda_folder": "Immunology"
}